XWELL Seeks Shareholder Approval for $13M Sale of Airport Spa and Testing Units
XWEL has more than doubled off its 52-week low of $0.255 on light trading volume (0.2× avg).
Summary
XWELL files a preliminary proxy seeking stockholder approval to sell its XpresSpa and XpresTest businesses for $13 million, pivoting away from unprofitable airport operations. The buyer has not yet secured financing, and the deal includes a fairness opinion, detailed financial projections, and a board recommendation in favor.
Key Events · M&A and Partnerships · XWEL
-
Sale Agreement Signed
On July 6, 2026, XWELL entered into a definitive agreement to sell its XpresSpa and XpresTest businesses to Express Wellness Group for a base purchase price of $13 million, subject to adjustments.
-
Stockholder Vote Required
Approval by a majority of outstanding shares is required for the sale. A special meeting will be held virtually, though the record date and meeting date have not yet been set.
-
Buyer Financing Uncertain
Express Wellness Group has not obtained debt or equity commitment letters. While the buyer is in active discussions with lenders, there is no guarantee financing will be secured, and the buyer's obligation to close is not conditioned on financing.
-
Fairness Opinion Obtained
Roth Capital Partners rendered a fairness opinion to the board, stating the consideration is fair from a financial point of view. The opinion employed a discounted cash flow analysis, selected public companies analysis, and precedent transactions.
Analysis · XWEL · Trade & Services
XWELL is asking shareholders to approve the $13 million cash sale of its XpresSpa and XpresTest businesses, marking a strategic pivot away from structurally challenged airport operations. XpresSpa has been unprofitable for years, and XpresTest relies on a single CDC contract. The proxy reveals that the buyer, Express Wellness Group, has not yet secured financing, though discussions with lenders are underway. If approved, the sale would leave XWELL with a much smaller ex-airport retail business and a pile of cash to pursue acquisitions in new industries. The board unanimously recommends voting in favor, and a fairness opinion from Roth Capital supports the price. However, the lack of committed financing and the company's tiny market cap add risk — if the deal falls through, XWELL could be on the hook for a $1.3 million termination fee.
At the time of this filing, XWEL was trading at $1.05 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $0.26 to $2.20. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.